Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of ETX2514 and Sulbactam in Renal Impairment
NCT03310463Phase 1Completed
- Sponsor
- Entasis Therapeutics
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durlobactam in Acinetobacter baumannii infection (5 cohorts), sponsored by Entasis Therapeutics. Primary endpoints: Maximum Observed Drug Concentration, Time to Reach Maximum Concentration and 10 more. Started Oct 2017; status: completed.
02
Drugs
durlobactam
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT03310463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310463.